Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells

被引:51
作者
Banes-Berceli, Amy K.
Shaw, Sean
Ma, Guochuan
Brands, Michael
Eaton, Douglas C.
Stern, David M.
Fulton, David
Caldwell, R. William
Marrero, Mario B. [1 ]
机构
[1] Med Coll Georgia, Dept Pharmacol & Toxicol, Vasc Biol Ctr, Augusta, GA 30912 USA
[2] Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA
[3] Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA
[4] Univ Cincinnati, Coll Med, Cincinnati, OH USA
关键词
diabetes; Rho GTPase; nephropathy;
D O I
10.1152/ajprenal.00502.2005
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 291: F116-F121, 2006. First published January 31, 2006; doi:10.1152/ajprenal.00502.2005.-In the current study, we investigated the effect of simvastatin on the ability of high glucose (HG) and ANG II to activate the JAK2-STAT signaling cascade and induce glomerular mesangial cell (GMC) growth. We found that pretreatment with simvastatin significantly inhibited HG- and ANG II-induced collagen IV production, JAK2 activation, and phosphorylation of STAT1 and STAT3 in GMC. We also found that the activation of JAK2 by HG and ANG II was dependent on the Rho family of GTPases. Consistent with these in vitro results, both albumin protein excretion and phosphorylation of JAK2, STAT1, and STAT3 were attenuated in renal glomeruli by administration of simvastatin in a streptozotocin-induced rat model of HG diabetes. This study demonstrates that simvastatin blocks ANG II-induced activation of the JAK/STAT pathway in the diabetic environment, in vitro and in vivo, and, thereby, provides new insights into the molecular mechanisms underlying early diabetic nephropathy.
引用
收藏
页码:F116 / F121
页数:6
相关论文
共 18 条
[1]   Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells [J].
Amiri, F ;
Venema, VJ ;
Wang, XD ;
Ju, H ;
Venema, RC ;
Marrero, MB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32382-32386
[2]   Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose [J].
Amiri, F ;
Shaw, S ;
Wang, XD ;
Tang, J ;
Waller, JL ;
Eaton, DC ;
Marrero, MB .
KIDNEY INTERNATIONAL, 2002, 61 (05) :1605-1616
[3]   Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli [J].
Banes, AK ;
Shaw, S ;
Jenkins, J ;
Redd, H ;
Amiri, F ;
Pollock, DM ;
Marrero, MB .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2004, 286 (04) :F653-F659
[4]  
Da Ros Roberto, 2004, Current Vascular Pharmacology, V2, P335
[5]   3-hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy [J].
Danesh, FR ;
Sadeghi, MM ;
Amro, N ;
Philips, C ;
Zeng, LX ;
Lin, S ;
Sahai, A ;
Kanwar, YS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) :8301-8305
[6]   Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function [J].
Epstein, M ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (01) :2-14
[7]   Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation [J].
Horiuchi, M ;
Cui, TX ;
Li, Z ;
Li, JM ;
Nakagami, H ;
Iwai, M .
CIRCULATION, 2003, 107 (01) :106-112
[8]  
Kim SI, 2000, J AM SOC NEPHROL, V11, P80, DOI 10.1681/ASN.V11180
[9]   HDL as a target in the treatment of atherosclerotic cardiovascular disease [J].
Linsel-Nitschke, P ;
Tall, AR .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) :193-205
[10]  
Malcolm Janine, 2003, Clin Evid, P690